Correction (DOI:10.1016/j.ahj.2007.11.029);Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: Results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10)

American Heart Journal

Volumn 155, Issue 4, 2008, Pages 712-717

  Wilcox, Robert ^a   Kupfer, Stuart ^b   Erdmann, Erland ^c  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b TAKEDA PHARMACEUTICALS   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STROKE;

EID: 40849134281     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.06.012     Document Type: Erratum

References (17)

1. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. Kannel W.B., and McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2 (1979) 120-126
3. Stamler J., Vaccaro O., Neaton J.D., et al., for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
4. Staels B. PPARγ and atherosclerosis. Curr Med Res Opin 21 (2005) S13-S20
5. Erdmann E. Diabetes and cardiovascular risk markers. Curr Med Res Opin 21 (2005) S21-S28
6. Charbonnel B., Dormandy J., Erdmann E., et al., PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27 (2004) 1647-1653
7. Dormandy J.A., Charbonnel B., Eckland E.J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 366 (2005) 1279-1289
8. Lindholm L.H., Ibsen H., Dahlöf B., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
9. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
10. Shepherd J., Blauw G.J., Murphy M.B., et al., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
11. Downs J.R., Clearfield M., Weis S., et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
12. Pyörälä K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
13. Goldberg R.B., Mellies M.J., Sacks F.M., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98 (1998) 2513-2519
14. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366 (2005) 1849-1861
15. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288 (2002) 2998-3007
16. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised trial. Lancet 361 (2003) 1149-1158
17. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357